Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) in patients who have received at least two prior lines of systemic therapy.
Age 18 years and older at the time of informed consent.
Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).
Relapsed or refractory disease, having previously received at least two lines of systemic therapy.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
Prior treatment with any CD20/CD3 bispecific antibodies or XPO1 inhibitors.
Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases.
Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection.
Active autoimmune diseases requiring systemic immunosuppressive therapy.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead sponsor
Zhejiang Provincial People's Hospital
Collaborator
The First Affiliated Hospital of Zhejiang Chinese Medical University
Collaborator
Zhejiang Provincial Tongde Hospital
Collaborator
Affiliated Hospital of Jiaxing University
Collaborator
Shaoxing People's Hospital
Collaborator
Shaoxing Central Hospital
Collaborator
Zhuji People's Hospital of Zhejiang Province
Collaborator